SGLT2 inhibitor linked to longer telomeres in diabetes trial
A randomized, double-blind trial of 150 adults with type 2 diabetes linked henagliflozina, an SGLT2 inhibitor, to longer telomeres after 26 weeks, compared with placebo.
Source: SGLT2 inhibitor linked to longer telomeres in diabetes trial (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
The randomized, double-blind trial followed 150 adults with type 2 diabetes for 26 weeks. Some participants received henagliflozina, an SGLT2 inhibitor, and others received a placebo. At the end of the period, telomere length increased significantly in the henagliflozina group compared with placebo.
Telomeres are structures at the ends of chromosomes and are proposed as a marker of cellular aging. That is why the finding draws attention, but it has important limits: the trial itself notes that the result does not prove aging has slowed. A changing marker does not automatically mean an effect on health or longevity, and larger, longer studies are needed to assess that.
What it means
The result suggests an association between henagliflozina use and longer telomeres in adults with type 2 diabetes. It is not yet known whether this change translates into slower aging or long-term health benefit.
How to read it with care
This trial does not replace a medical consultation. Anyone considering a change in diet, supplements or treatment should talk to a doctor or another qualified health professional.